Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis

Francesca Chamian; Shao Lee Lin; Edmund Lee; Toyoko Kikuchi; Patricia Gilleaudeau; Mary Sullivan-Whalen; Irma Cardinale; Artemis Khatcherian; Inna Novitskaya; Knut M. Wittkowski; James G. Krueger; Michelle A. Lowes

doi:10.1186/1479-5876-5-27

Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis

Francesca Chamian
, Shao Lee Lin
, Edmund Lee
, Toyoko Kikuchi
, Patricia Gilleaudeau
, Mary Sullivan-Whalen
, Irma Cardinale
, Artemis Khatcherian
, Inna Novitskaya
, Knut M. Wittkowski
, James G. Krueger
, Michelle A. Lowes

Research output: Contribution to journal › Article › peer-review

71 Scopus citations

Abstract

Background: Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease. Methods: Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis. Results: In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7- CD45RA-) (mean 63% reduction) for both CD4⁺ and CD8⁺ Tem, while central memory T cells (Tcm) (CCR7⁺CD45RA-) were less affected, and naïve T cells (CCR7⁺CD45RA^-) were relatively spared. Circulating CD8⁺ effector T cells and Type 1 T cells (IFN-γ-producing) were also significantly reduced. Conclusion: Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.

Original language	English (US)
Article number	27
Journal	Journal of Translational Medicine
Volume	5
DOIs	https://doi.org/10.1186/1479-5876-5-27
State	Published - Jun 7 2007
Externally published	Yes

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1186/1479-5876-5-27

Cite this

Chamian, F., Lin, S. L., Lee, E., Kikuchi, T., Gilleaudeau, P., Sullivan-Whalen, M., Cardinale, I., Khatcherian, A., Novitskaya, I., Wittkowski, K. M., Krueger, J. G., & Lowes, M. A. (2007). Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. Journal of Translational Medicine, 5, Article 27. https://doi.org/10.1186/1479-5876-5-27

Chamian, F, Lin, SL, Lee, E, Kikuchi, T, Gilleaudeau, P, Sullivan-Whalen, M, Cardinale, I, Khatcherian, A, Novitskaya, I, Wittkowski, KM, Krueger, JG & Lowes, MA 2007, 'Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis', Journal of Translational Medicine, vol. 5, 27. https://doi.org/10.1186/1479-5876-5-27

@article{e8449bc854614c91aa6221a98d5d7577,

title = "Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis",

abstract = "Background: Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease. Methods: Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis. Results: In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7- CD45RA-) (mean 63\% reduction) for both CD4+ and CD8+ Tem, while central memory T cells (Tcm) (CCR7+CD45RA-) were less affected, and na{\"i}ve T cells (CCR7+CD45RA-) were relatively spared. Circulating CD8+ effector T cells and Type 1 T cells (IFN-γ-producing) were also significantly reduced. Conclusion: Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.",

author = "Francesca Chamian and Lin, \{Shao Lee\} and Edmund Lee and Toyoko Kikuchi and Patricia Gilleaudeau and Mary Sullivan-Whalen and Irma Cardinale and Artemis Khatcherian and Inna Novitskaya and Wittkowski, \{Knut M.\} and Krueger, \{James G.\} and Lowes, \{Michelle A.\}",

year = "2007",

month = jun,

day = "7",

doi = "10.1186/1479-5876-5-27",

language = "English (US)",

volume = "5",

journal = "Journal of Translational Medicine",

issn = "1479-5876",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis

AU - Chamian, Francesca

AU - Lin, Shao Lee

AU - Lee, Edmund

AU - Kikuchi, Toyoko

AU - Gilleaudeau, Patricia

AU - Sullivan-Whalen, Mary

AU - Cardinale, Irma

AU - Khatcherian, Artemis

AU - Novitskaya, Inna

AU - Wittkowski, Knut M.

AU - Krueger, James G.

AU - Lowes, Michelle A.

PY - 2007/6/7

Y1 - 2007/6/7

N2 - Background: Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease. Methods: Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis. Results: In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7- CD45RA-) (mean 63% reduction) for both CD4+ and CD8+ Tem, while central memory T cells (Tcm) (CCR7+CD45RA-) were less affected, and naïve T cells (CCR7+CD45RA-) were relatively spared. Circulating CD8+ effector T cells and Type 1 T cells (IFN-γ-producing) were also significantly reduced. Conclusion: Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.

AB - Background: Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease. Methods: Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis. Results: In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7- CD45RA-) (mean 63% reduction) for both CD4+ and CD8+ Tem, while central memory T cells (Tcm) (CCR7+CD45RA-) were less affected, and naïve T cells (CCR7+CD45RA-) were relatively spared. Circulating CD8+ effector T cells and Type 1 T cells (IFN-γ-producing) were also significantly reduced. Conclusion: Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.

UR - https://www.scopus.com/pages/publications/34447329553

UR - https://www.scopus.com/pages/publications/34447329553#tab=citedBy

U2 - 10.1186/1479-5876-5-27

DO - 10.1186/1479-5876-5-27

M3 - Article

C2 - 17555598

AN - SCOPUS:34447329553

SN - 1479-5876

VL - 5

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

M1 - 27

ER -

Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this